NCT00054886View on ClinicalTrials.gov

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

August 31, 2004

Conditions
Kidney Neoplasms
Interventions
DRUG

SU-011,248

Trial Locations (15)

10021

Pfizer Investigational Site, New York

19111

Pfizer Investigational Site, Philadelphia

48109

Pfizer Investigational Site, Ann Arbor

53792

Pfizer Investigational Site, Madison

89052

Pfizer Investigational Site, Henderson

89109

Pfizer Investigational Site, Las Vegas

89128

Pfizer Investigational Site, Las Vegas

90095

Pfizer Investigational Site, Los Angeles

91328

Pfizer Investigational Site, Northridge

91345

Pfizer Investigational Site, Mission Hills

91754

Pfizer Investigational Site, Monterey Park

94115

Pfizer Investigational Site, San Francisco

94121

Pfizer Investigational Site, San Francisco

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00054886 - Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter